Checkpoint Capital L.P. Acquires New Position in Septerna, Inc. $SEPN

Key Points

• Checkpoint Capital L.P. has acquired a new stake in Septerna, Inc., purchasing 824,878 shares valued at approximately $4.8 million, making it the 8th largest position in their portfolio.
• Several institutions, including Tower Research Capital and Deutsche Bank AG, have also recently acquired stakes in Septerna while other fund managers have increased their existing holdings.
• Wall Street analysts hold a consensus rating of "Moderate Buy" for Septerna with a target price of $26.75, despite the company reporting a negative earnings per share of ($0.56).

Checkpoint Capital L.P. acquired a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 824,878 shares of the company's stock, valued at approximately $4,776,000. Septerna comprises about 2.6% of Checkpoint Capital L.P.'s investment portfolio, making the stock its 8th biggest position. Checkpoint Capital L.P. owned about 1.85% of Septerna as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in Septerna during the fourth quarter worth $25,000. BNP Paribas Financial Markets acquired a new stake in Septerna during the 4th quarter worth $52,000. Rhumbline Advisers boosted its stake in Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock worth $135,000 after purchasing an additional 3,323 shares during the last quarter. Deutsche Bank AG boosted its stake in Septerna by 53.3% during the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock worth $92,000 after purchasing an additional 5,549 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Septerna during the 1st quarter worth $49,000.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SEPN. Wells Fargo & Company lifted their target price on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $26.00 price target on shares of Septerna in a research report on Thursday, August 21st. Wall Street Zen cut shares of Septerna from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Finally, Cantor Fitzgerald boosted their price target on shares of Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Septerna has a consensus rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Trading Up 14.1%

Shares of SEPN opened at $14.08 on Thursday. The firm has a market cap of $627.76 million and a P/E ratio of -1.40. Septerna, Inc. has a 12-month low of $4.17 and a 12-month high of $28.99. The company's 50-day moving average price is $11.96 and its 200 day moving average price is $9.04.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to analysts' expectations of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. Equities research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

Want to see what other hedge funds are holding SEPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Septerna, Inc. (NASDAQ:SEPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.